Edwards Lifesciences v Meril Italy (CFI, 13 November 2023)
| Date | 13 November 2023 |
|---|---|
| Court | CFI |
| Division | Paris (FR) Central Division - Seat |
| Type of action | Preliminary objection |
| Case number(s) | UPC_CFI_255/2023 |
| Registry reference | ORD_578356/2023 · UPC_CFI_255/2023 |
| Parties | Edwards Lifesciences Corporation v. Meril Italy srl |
Official decision (PDF) · UPC registry entry
Case timeline
- 27 February 2024 : Meril Italy v Edwards Lifesciences (CFI, UPC_CFI_255/2023, ORD_7184/2024, 27 February 2024) ORD_7184/2024 · App_7184/2024 · UPC_CFI_255/2023
- 27 February 2024 : Meril Italy v Edwards Lifesciences (CFI, UPC_CFI_255/2023, ORD_7184/2024, 27 February 2024, doc. 2) App_7184/2024 · ORD_7184/2024 · UPC_CFI_255/2023
- 30 April 2024 : Edwards Lifesciences v Meril Italy (CFI, 30 April 2024) App_19959/2024and23242/2024 · ORD_24620/2024 · UPC_CFI_255/2023
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By an order of 13 November 2023 (UPC_CFI_255/2023, ACT_551308/2023, App_572915/2023), the judge-rapporteur of panel 2 of the Paris Central Division (P. Catallozzi) rejected the Preliminary objection of Edwards Lifesciences Corporation, which argued that Meril Italy srl’s revocation action against EP 3 646 825 had to be brought before the Munich Local Division, where an infringement action was pending against Meril Life Sciences and Meril GmbH. He also rejected the request for security for costs.
Question
Is a separate subsidiary of the group sued for infringement the « same party » within Art. 33(4) UPCA, so that the central division lacks competence?
Decision
As the Agreement does not define a party, the question is one for national law, here Italian law, under which legal persons with separate personality are different parties, whatever their shareholding links (paragraphs 35 to 43). The CJEU case law on lis pendens does not apply, the Agreement having its own rules, and the exception to the central division’s competence for revocation is to be construed narrowly (paragraphs 44 to 55). The straw company argument fails for want of evidence of an arrangement shifting the effects of the action onto another entity (paragraphs 56 to 69). The risk of conflicting decisions is addressed by the Agreement’s tools (referral, stay), and multiple actions by linked companies are not abusive in themselves (paragraphs 70 to 84). Security for costs may be sought with the Preliminary objection, but share capital of EUR 10,000 and the lack of activity are not enough, given membership of the group (paragraphs 88 to 91).
Key points for practice
- Practical point: a group company not sued before the local division may bring a revocation action before the central division, the proprietor must prove genuine interposition to obtain a transfer.
Provisions applied
- Agreement on a Unified Patent Court
- Art. 33(2) to (6), Art. 46, Art. 47(6) and Art. 69(4)
- Rules of Procedure
- Rules 19, 48, 158, 295, 302, 303, 331 and 340
- European Patent Convention
- Art. 68
- Regulation (EU) No 1215/2012
- Art. 29
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Decisions in the same proceedings
Going further
Lexicon: Local and central divisions (UPC).
Dhenne Avocats blog: The Transitional Period and the UPC: Coordinating Two Judicial Orders.
Publications by Matthieu Dhenne: Pleading the Long Arm: What a UPC Statement of Claim Must Carry Beyond Jurisdiction, Valeo v. Bosch and the Redistribution of Cases Within the UPC (Kluwer Patent Blog).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- claimantEdwards Lifesciences Corporation41 decisions in the corpusFollow this party
- defendantMeril Italy srl19 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
- 13 November 2023 Edwards Lifesciences v Meril Italy (CFI, 13 November 2023) Preliminary objection · UPC_CFI_255/2023
- 27 February 2024 Meril Italy v Edwards Lifesciences (CFI, UPC_CFI_255/2023, ORD_7184/2024, 27 February 2024) Generic application · UPC_CFI_255/2023
- 27 February 2024 Meril Italy v Edwards Lifesciences (CFI, UPC_CFI_255/2023, ORD_7184/2024, 27 February 2024, doc. 2) Generic application · UPC_CFI_255/2023
- 30 April 2024 Edwards Lifesciences v Meril Italy (CFI, 30 April 2024) Generic application · UPC_CFI_255/2023
La demande ultérieure de modification du brevet est admise et Meril dispose d'un mois pour une défense complémentaire. La duplique est refusée.
What the record states
- Nature of the act
- Preliminary objection
- Outcome (Dhenne Avocats summary)
- La division centrale reste compétente pour l'action en nullité de Meril Italy, filiale distincte des défenderesses à l'action en contrefaçon munichoise. La garantie pour les frais est refusée.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 3 646 825mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- Edwards Lifesciences v Meril Italy (CFI, 30 April 2024) cited in this record
- Meril Italy v Edwards Lifesciences (CFI, UPC_CFI_255/2023, ORD_7184/2024, 27 February 2024) cited in this record
- Meril Italy v Edwards Lifesciences (CFI, UPC_CFI_255/2023, ORD_7184/2024, 27 February 2024, doc. 2) cited in this record
- ALD France v Nanoval (CFI, 26 January 2026) cites this decision
- ALD France v Nanoval (CFI, 9 December 2025) cites this decision
- Seoul Viosys v Emporia UK (CFI, 1 September 2025) cites this decision
- Pfizer v GlaxoSmithKline Biologicals (CFI, 3 December 2024) cites this decision
- Edwards Lifesciences v Meril Life Sciences (CFI, 15 November 2024) cites this decision
- Volkswagen v Network System Technologies (CFI, ORD_12231/2024, 23 April 2024) cites this decision
- Network System Technologies v Volkswagen (CFI, 23 April 2024) cites this decision
- Volkswagen v Network System Technologies (CFI, ORD_12484/2024, 23 April 2024) cites this decision
- Volkswagen v Network System Technologies (CFI, ORD_12483/2024, 23 April 2024) cites this decision
- Volkswagen v Network System Technologies (CFI, ORD_17417/2024, 23 April 2024) cites this decision
- Meril Italy v Edwards Lifesciences (CFI, 28 February 2024) cites this decision
- Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 20 November 2023) cites this decision
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 3 646 825A system comprising a prosthetic valve and a delivery catheter recorded proprietor: Edwards Lifesciences Corp | Mentioned in the analysis (role not qualified) Also mentioned in 32 other decision(s): Edwards Lifesciences v Meril Life Sciences (CFI, 15 November 2024) · Meril Italy v Edwards Lifesciences (CFI, 19 July 2024) · Meril v Edwards Lifesciences (CFI, 19 July 2024) · Meril Italy v Edwards Lifesciences (CoA, 25 November 2025) · Edwards Lifesciences v Sintec (CFI, 5 September 2025) · Meril Italy v SWAT Medical (CoA, 5 May 2025) · Meril v SWAT Medical (CoA, 5 May 2025) · Meril Life Sciences v SWAT Medical (CoA, 5 May 2025) | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.